Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,shortTermInvestments,accountsPayable,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,currency,postMarketPrice,postMarketChange,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,postMarketChangePercent,postMarketTime,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,gmtOffSetMilliseconds,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,priceHint,shortName,longName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchange,market,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,exchangeDataDelayedBy,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Apr 29, 2021) 4","Short Ratio (Apr 29, 2021) 4","Short % of Float (Apr 29, 2021) 4","Short % of Shares Outstanding (Apr 29, 2021) 4","Shares Short (prior month Mar 30, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,GRTX,-13712000,25254100,12423000,,-18715000,,-18715000,5058000,0,-17481000,-17481000,,-1253000,,,,0,0,17481000,0,-1234000,,-18715000,-18715000,2258000,243675000,81059000,-10573000,70486000,25000,-254283000,64969000,881000,10000,1477000,13687000,15855000,10000,1630000,64240000,43833000,9217000,13069000,4071000,12883000,235000,-3809000,235000,-2185000,-15303000,106000,3044000,-186000,48385000,en-US,US,EQUITY,True,Delayed Quote,USD,8.33,0.09000015,-8.035717,8.12 - 9.01,8.96,0.0,0.0,14,8,finmb_225098093,NasdaqGM,USD,118512,64057,2.37,0.40374786,5.87 - 15.0,-6.76,-0.4506667,5.87,15.0,1615469400,1615469400,1615469400,1.0922348,1630539143,-173.088,-2.35,-3.15,-2.6158729,-14400000,-481.109,8.747714,-0.5077143,-0.05803965,9.033913,-0.7939129,2,"Galera Therapeutics, Inc.","Galera Therapeutics, Inc.",8.24,1630526403,-0.72000027,9.0,9.01,8.12,179268,PREPRE,NGM,us_market,-0.0878814,208093776,-3.506383,-0.017127095,15,America/New_York,EDT,False,False,0,,,,15.0,5.87,8.75,9.03,118.51k,64.06k,25.25M,,7.43M,11.42%,80.11%,326.66k,0.24,2.27%,1.29%,153.23k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-43.60%,-350.79%,,,,,-69.82M,-74.52M,-173.09,,57.52M,2.28,531k,,4.05,-481.11,-62.45M,-40.15M,Value,19355,Healthcare,38,8,2,"Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.",Malvern,610 725 1500,PA,8,1609372800,1619740800,9,United States,http://www.galeratx.com,86400,8,2 West Liberty Boulevard,Biotechnology,Suite 100
t-1,GRTX,2979000,25254100,14620000,,-20082000,,-20066000,4324000,0,-18944000,-18944000,,-1255000,,,,-16000,0,18944000,0,-1138000,,-20066000,-20066000,2258000,241649000,77980000,6118000,84098000,25000,-235568000,63716000,881000,12000,1477000,15872000,13968000,12000,1553000,77929000,56904000,5146000,16904000,1133000,16858000,232000,-220000,232000,640000,-16450000,96000,2607000,-46000,63961000,en-US,US,EQUITY,True,Delayed Quote,USD,8.33,0.09000015,-8.035717,8.12 - 9.01,8.96,0.0,0.0,14,8,finmb_225098093,NasdaqGM,USD,118512,64057,2.37,0.40374786,5.87 - 15.0,-6.76,-0.4506667,5.87,15.0,1615469400,1615469400,1615469400,1.0922348,1630539143,-173.088,-2.35,-3.15,-2.6158729,-14400000,-481.109,8.747714,-0.5077143,-0.05803965,9.033913,-0.7939129,2,"Galera Therapeutics, Inc.","Galera Therapeutics, Inc.",8.24,1630526403,-0.72000027,9.0,9.01,8.12,179268,PREPRE,NGM,us_market,-0.0878814,208093776,-3.506383,-0.017127095,15,America/New_York,EDT,False,False,0,,,,15.0,5.87,8.75,9.03,118.51k,64.06k,25.25M,,7.43M,11.42%,80.11%,326.66k,0.24,2.27%,1.29%,153.23k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-43.60%,-350.79%,,,,,-69.82M,-74.52M,-173.09,,57.52M,2.28,531k,,4.05,-481.11,-62.45M,-40.15M,Value,19355,Healthcare,38,8,2,"Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.",Malvern,610 725 1500,PA,8,1609372800,1619740800,9,United States,http://www.galeratx.com,86400,8,2 West Liberty Boulevard,Biotechnology,Suite 100
t-2,GRTX,21556000,25254100,12133000,,-17078000,,-17078000,3945000,0,-16078000,-16078000,,-1235000,,,,0,0,16078000,0,-1000000,,-17078000,-17078000,2258000,240049000,73380000,24695000,98075000,25000,-215502000,62521000,881000,123000,956000,15232000,10503000,123000,1676000,92304000,73919000,4013000,14415000,-2754000,14410000,224000,1711000,224000,-650000,-15284000,97000,2740000,-5000,81801000,en-US,US,EQUITY,True,Delayed Quote,USD,8.33,0.09000015,-8.035717,8.12 - 9.01,8.96,0.0,0.0,14,8,finmb_225098093,NasdaqGM,USD,118512,64057,2.37,0.40374786,5.87 - 15.0,-6.76,-0.4506667,5.87,15.0,1615469400,1615469400,1615469400,1.0922348,1630539143,-173.088,-2.35,-3.15,-2.6158729,-14400000,-481.109,8.747714,-0.5077143,-0.05803965,9.033913,-0.7939129,2,"Galera Therapeutics, Inc.","Galera Therapeutics, Inc.",8.24,1630526403,-0.72000027,9.0,9.01,8.12,179268,PREPRE,NGM,us_market,-0.0878814,208093776,-3.506383,-0.017127095,15,America/New_York,EDT,False,False,0,,,,15.0,5.87,8.75,9.03,118.51k,64.06k,25.25M,,7.43M,11.42%,80.11%,326.66k,0.24,2.27%,1.29%,153.23k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-43.60%,-350.79%,,,,,-69.82M,-74.52M,-173.09,,57.52M,2.28,531k,,4.05,-481.11,-62.45M,-40.15M,Value,19355,Healthcare,38,8,2,"Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.",Malvern,610 725 1500,PA,8,1609372800,1619740800,9,United States,http://www.galeratx.com,86400,8,2 West Liberty Boulevard,Biotechnology,Suite 100
t-3,GRTX,37098000,25254100,13839000,,-18657000,,-18657000,3874000,0,-17713000,-17713000,,-1295000,,,,0,0,17713000,0,-944000,,-18657000,-18657000,2258000,238320000,74058000,40237000,114295000,25000,-198424000,61242000,881000,316000,918000,15882000,12402000,316000,1840000,108398000,88527000,6767000,10042000,127000,9674000,41000,276000,41000,-5696000,-15411000,95000,2748000,-368000,95996000,en-US,US,EQUITY,True,Delayed Quote,USD,8.33,0.09000015,-8.035717,8.12 - 9.01,8.96,0.0,0.0,14,8,finmb_225098093,NasdaqGM,USD,118512,64057,2.37,0.40374786,5.87 - 15.0,-6.76,-0.4506667,5.87,15.0,1615469400,1615469400,1615469400,1.0922348,1630539143,-173.088,-2.35,-3.15,-2.6158729,-14400000,-481.109,8.747714,-0.5077143,-0.05803965,9.033913,-0.7939129,2,"Galera Therapeutics, Inc.","Galera Therapeutics, Inc.",8.24,1630526403,-0.72000027,9.0,9.01,8.12,179268,PREPRE,NGM,us_market,-0.0878814,208093776,-3.506383,-0.017127095,15,America/New_York,EDT,False,False,0,,,,15.0,5.87,8.75,9.03,118.51k,64.06k,25.25M,,7.43M,11.42%,80.11%,326.66k,0.24,2.27%,1.29%,153.23k,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-43.60%,-350.79%,,,,,-69.82M,-74.52M,-173.09,,57.52M,2.28,531k,,4.05,-481.11,-62.45M,-40.15M,Value,19355,Healthcare,38,8,2,"Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer (HNC); and in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; in phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy; and has completed pilot placebo-controlled Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) for patients with locally advanced pancreatic cancer, as well as in Phase II clinical trial for hospitalized patients with COVID-19 disease. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with SBRT in patients with non-small cell lung cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.",Malvern,610 725 1500,PA,8,1609372800,1619740800,9,United States,http://www.galeratx.com,86400,8,2 West Liberty Boulevard,Biotechnology,Suite 100
